ClinicalTrials.gg
CompletedNCT00220272Updated Dec 23, 2008

Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

A Phase 2 interventional study of SR57667B in Parkinson Disease, sponsored by Sanofi. Completed at 7 sites in 7 countries. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2008-12-23.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
35 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Enrollment
62nd of 212
183 · median 60
Started
2004
with 3 others
Phase 2
40 of 253
3 open now
Registered
9th of 253
by date

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 62nd largest by enrollment of the 212 interventional ones that give a count, is one of 4 that started in 2004, is one of 40 in phase 2, and was the 9th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 35 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

  • The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging.
  • Secondary objectives are to assess the effect of SR57667B on symptomatic decline in patients with early PD, to assess the safety/tolerability of SR57667B in patients with early PD and to document plasma concentrations of SR57667 in patients with early PD.
Read the detailed description

Multinational, multicenter, randomized, parallel-group, double-blind, phase II study.Randomization stratified on the dopaminergic treatment, in two strata: treatment by levodopa or dopamine agonist.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • 5-fluorodopa
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients.
  • Age >=35 years at screening.
  • Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's symptoms, i.e. resting tremor, bradykinesia and rigidity.
  • Duration of the disease of less than 3 years since diagnosis.
  • Modified Hoehn and Yahr stage \<= 2.5.
  • Patient optimized on monotherapy by levodopa or a dopamine agonist·
  • Generally healthy and ambulatory.
  • Patient has given his informed written consent and is capable of following study procedures.

Exclusion criteria

Exclusion Criteria:

  • Any indication of forms of parkinsonism other than PD.
  • Severe resting tremor. Presence of either dyskinesia, fluctuations, or loss of postural reflexes·
  • Treatment with amantadine, anticholinergics, catechol-o-methyltransferase (COMT ) inhibitors, selegiline, dopamine receptor antagonists, catecholamine depleters, indirect dopamine agonists or alphamethyldopa. Electroconvulsive therapy (ECT).Use of strong, and moderate inducers or inhibitors. Participation in another clinical trial with an drug within two months prior to randomization.
  • Dementia, uncontrolled depression, psychotic disorder. History of substance-related disorders including alcohol or other substance use disorders.
  • Females of child bearing potential.
  • Evidence (detected by history, physical examination and/or laboratory/ tests) of any or unstable medical disorder that could interfere with the patient's participation in the clinical trial; interfere with the absorption, metabolism or excretion of the study medication; or interfere with the evaluation of the study drug. Alterations of laboratory tests or ECG findings of potential clinical significance.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
183 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in average (left and right) putamen 18F-Dopa influx constant (Ki) from baseline to two year 18F-Dopa PET

Secondary outcomes

  1. Unified Parkinson's Disease Rating Scale (UPDRS)

07

Study locations

7 sites
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2005
First posted
Sep 22, 2005
Start
Jan 2004
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Dec 23, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00220272
Lead sponsor
Sanofi
First posted
Sep 22, 2005
Start date
Jan 2004
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Dec 23, 2008

Study contacts

Philippe Remy, MD
study chair · Service Hospitalier Frédéric Joliot, CEA, Orsay France
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliroden

Start the discussion